LON:INDV Indivior (INDV) Share Price, News & Analysis → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free INDV Stock Alerts GBX 1,393.34 -6.66 (-0.48%) (As of 04:32 AM ET) Add Compare Share Share Today's Range 1,364▼ 1,40750-Day Range 1,314▼ 1,76452-Week Range 1,125▼ 1,938Volume957,362 shsAverage Volume399,414 shsMarket Capitalization£1.89 billionP/E Ratio139,333.70Dividend Yield1.08%Price TargetGBX 2,515 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesStock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider Trades Get Indivior alerts: Email Address Indivior MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside79.6% UpsideGBX 2,515 Price TargetShort InterestN/ADividend StrengthWeakBased on Four FactorsSustainabilityN/ANews Sentiment0.10Based on 2 Articles This WeekInsider TradingSelling Shares£42.45 M Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.20 out of 5 stars 3.5 Analyst's Opinion Consensus RatingIndivior has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageIndivior has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for INDV. Previous Next 1.7 Dividend Strength Dividend LeadershipIndivior is a leading dividend payer. It pays a dividend yield of 4.48%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthIndivior does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Indivior is 150,000.00%. Payout ratios above 75% are not desirable because they may not be sustainable. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for INDV. Previous Next 1.7 News and Social Media Coverage News SentimentIndivior has a news sentiment score of 0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Indivior this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for INDV on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Indivior insiders have sold more of their company's stock than they have bought. Specifically, they have bought GBX 0 in company stock and sold £424,476.69 in company stock.Percentage Held by InsidersOnly 3.21% of the stock of Indivior is held by insiders.Percentage Held by Institutions92.94% of the stock of Indivior is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Indivior is 140,000.00, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 144.03.Price to Earnings Ratio vs. SectorThe P/E ratio of Indivior is 140,000.00, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 256.45.Price to Earnings Growth RatioDue to a projected decrease in earnings for Indivior, their PEG ratio cannot be calculated. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 About Indivior Stock (LON:INDV)Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Read More INDV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INDV Stock News HeadlinesApril 26, 2024 | finance.yahoo.comWhy Indivior PLC (LON:INDV) Looks Like A Quality CompanyApril 14, 2024 | nasdaq.comNotable Two Hundred Day Moving Average Cross - INDVApril 26, 2024 | True Market Insiders (Ad)The “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…March 12, 2024 | msn.comThis Nasal Spray Rapidly Reverses Effects Of Fentanyl Overdose And No, It's Not NaloxoneFebruary 29, 2024 | markets.businessinsider.comIndivior Says Final Court Approval Concludes Antitrust Multidistrict LitigationFebruary 24, 2024 | reuters.comEurope's STOXX 600 at all-time high as Nvidia boosts global tech sharesFebruary 22, 2024 | msn.comIndivior weighs moving primary listing to U.S.February 10, 2024 | finance.yahoo.comIndivior PLC (LON:INDV) Shares Could Be 44% Below Their Intrinsic Value EstimateApril 26, 2024 | True Market Insiders (Ad)The “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…January 18, 2024 | markets.businessinsider.comAdial Announces Appointment of Tony Goodman as Chief Operating OfficerNovember 20, 2023 | finance.yahoo.comGreat week for Indivior PLC (LON:INDV) institutional investors after losing 22% over the previous yearNovember 9, 2023 | msn.comIndivior PLC (INDV) Tops Q3 Earnings and Revenue EstimatesOctober 2, 2023 | finance.yahoo.comIndivior PLC (INDV): Unveiling Its Market ValueSeptember 26, 2023 | finance.yahoo.comIndivior Publishes Real World Data Showing SUBLOCADE® May Reduce Non-Fatal Overdoses Among Individuals with Opioid Use Disorder in CanadaSeptember 7, 2023 | finance.yahoo.comIndivior PLC (INDV)'s True Worth: A Complete Analysis of Its Market ValueJune 12, 2023 | finance.yahoo.comThe 7.5% return this week takes Indivior's (LON:INDV) shareholders three-year gains to 372%June 12, 2023 | finance.yahoo.comIndivior to Commence Trading on NasdaqJune 7, 2023 | msn.comJefferies Reiterates Indivior (LSE:INDV) Buy RecommendationJune 5, 2023 | reuters.comIndivior opioid settlement makes purer M&A caseJune 3, 2023 | msn.comUS drugmaker Indivior to pay $102.5 million to settle Suboxone monopoly claimsJune 2, 2023 | finanznachrichten.deIndivior PLC: Indivior Reaches Agreement with States' Attorneys General and District of Columbia to Resolve Antitrust Multi-District Litigation ClaimsMay 25, 2023 | uk.finance.yahoo.comINDV.L - Indivior PLCMay 25, 2023 | finance.yahoo.comIndivior To Participate In Upcoming Investor ConferencesMay 23, 2023 | finance.yahoo.comIndivior PLC Form 20-F Registration Statement for Additional US Listing Now Available; Trading on NASDAQ Expected to Commence on June 12thMay 22, 2023 | markets.businessinsider.comFDA Approves Opiant's Nasal Spray 'Opvee' To Reverse Opioid OverdoseMay 22, 2023 | reuters.comUS FDA approves Opiant's spray for reversing opioid-related overdosesMay 22, 2023 | finance.yahoo.comIndivior Announces U.S. Food and Drug Administration Approval of OPVEE® (nalmefene) Nasal Spray, An Opioid Overdose Rescue Medicine for Natural and Synthetic Opioids Like FentanylSee More Headlines Receive INDV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Indivior and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolLON:INDV CUSIPN/A CIKN/A Webindivior.com Phone+44-1753-217800FaxN/AEmployees1,164Year FoundedN/APrice Target and Rating Average Stock Price TargetGBX 2,515 High Stock Price TargetGBX 2,700 Low Stock Price TargetGBX 2,330 Potential Upside/Downside+79.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)GBX 0.01 Trailing P/E Ratio140,000.00 Forward P/E Ratio1,320.75 P/E Growth-5.57Net Income£2 million Net Margins0.18% Pretax MarginN/A Return on Equity7.84% Return on Assets8.73% Debt Debt-to-Equity Ratio240.17 Current Ratio0.97 Quick Ratio1.52 Sales & Book Value Annual Sales£1.09 billion Price / Sales1.75 Cash FlowGBX 522.37 per share Price / Cash Flow2.68 Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares135,940,000Free FloatN/AMarket Cap£1.90 billion OptionableNot Optionable Beta-0.05 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Mark CrossleyCEO & Executive DirectorMr. Ryan PreblickCFO & Executive DirectorDr. Christian HeidbrederChief Scientific OfficerMr. Jason ThompsonVice President of Investor RelationsMs. Cynthia CetaniChief Integrity & Compliance OfficerMr. Jeffrey W. Burris (Age 52)Chief Legal Officer Mr. Jon FogleChief Human Resources OfficerMr. Richard SimkinChief Commercial OfficerMr. Hillel WestChief Manufacturing & Supply OfficerMr. Vishal KaliaSVP of US Treatment Access, Support Programs & Business Insights and Chief Impact & Strategy OfficerMore ExecutivesKey CompetitorsHUTCHMEDLON:HCMHikma PharmaceuticalsLON:HIKUDG HealthcareLON:UDGAbcamLON:ABCClinigen GroupLON:CLINView All CompetitorsInsidersMark CrossleySold 10,549 sharesTotal: £17.06 M ($1,617.00/share)Mark CrossleySold 15,444 sharesTotal: £25.39 M ($1,644.00/share)Graham HetheringtonBought 1,743 shares on 12/20/2023Total: £2.07 M ($1,189.00/share)Graham HetheringtonBought 2,650 shares on 11/20/2023Total: £3.58 M ($1,350.00/share)View All Insider Transactions INDV Stock Analysis - Frequently Asked Questions Should I buy or sell Indivior stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Indivior in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" INDV shares. View INDV analyst ratings or view top-rated stocks. What is Indivior's stock price target for 2024? 1 Wall Street analysts have issued 12 month price objectives for Indivior's shares. Their INDV share price targets range from GBX 2,330 to GBX 2,700. On average, they predict the company's stock price to reach GBX 2,515 in the next twelve months. This suggests a possible upside of 79.6% from the stock's current price. View analysts price targets for INDV or view top-rated stocks among Wall Street analysts. How have INDV shares performed in 2024? Indivior's stock was trading at GBX 1,185 at the beginning of the year. Since then, INDV shares have increased by 18.1% and is now trading at GBX 1,400. View the best growth stocks for 2024 here. Is Indivior a good dividend stock? Indivior (LON:INDV) pays an annual dividend of GBX 15 per share and currently has a dividend yield of 4.48%. INDV has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 150,000.00%. Payout ratios above 75% are not desirable because they may not be sustainable. What other stocks do shareholders of Indivior own? Based on aggregate information from My MarketBeat watchlists, some companies that other Indivior investors own include Bigblu Broadband (BBB), Futura Medical (FUM), Directa Plus (DCTA), Lakehouse (LAKE), Aquila Services Group (AQSG), Benchmark (BMK), Bodycote (BOY), CityFibre Infrastructure (CITY), Deltex Medical Group (DEMG) and Kingfisher (KGF). How do I buy shares of Indivior? Shares of INDV stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:INDV) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsThe World's First "$20 Trillion Drug?"Behind the MarketsI’m afraid WWIII is a very real possibility Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indivior PLC Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.